Introduction and Objective: In individuals with T1D, increased change in CGM (ΔG) is common during physical activity (PA) due to 3 main factors: impaired endogenous glucose production (ΔGegp), increased insulin-dependent glucose utilization (ΔGid), and increased insulin-independent glucose clearance (ΔGii) by skeletal muscles. To understand how the factors affect ΔG during PA, we identify a data-driven weighted sum model using the 4 most common PAs from the T1DEXI dataset.Methods: To account for glucose dynamics with a scalar value, we used the glucose area under the curve (AUC) of ΔG of each component. We estimated the 3 component weights by minimizing the difference between the sum of the 3 AUCs and the measured total AUC of ΔG. For identification, we used PA sessions with positive net insulin on board (netIOB) at PA onset, where netIOB was defined as the changes in insulin delivery relative to the basal rate.Results: We used 175 sessions of strength training, 201 biking, 123 jogging, and 515 walking. For small netIOB at the PA onset, ΔGii is predominant over the ΔGid, while ΔGii becomes more pronounced for increasing netIOB (Fig. 1). For PA >120 min, both ΔGii and ΔGid heavily contributed to overall ΔG for increasing netIOB. ΔGegp was much smaller than ΔGii or ΔGid.Conclusion: The proposed model constitutes a tool to reproduce real-life scenarios in simulation and is appealing for control design due to its simplicity.
E. Aiello: Research Support; Hemsley Charitable Trust. K. Tang: Research Support; Hemsley Charitable Trust. M.P. Dhaliwal: Research Support; Hemsley Charitable Trust. R. Lal: Consultant; Abbott, Biolinq, Capillary Biomedical, Inc, Gluroo, PhysioLogic Devices, Portal Insulin, Sanofi, Tidepool. Advisory Panel; Provention Bio, Inc, Provention Bio, Inc, Microbion, Microbion, Lilly Diabetes. Research Support; Insulet Corporation, Medtronic, Tandem Diabetes Care, Inc, Sinocare Inc. C. Summers: Consultant; Tidepool. M. Connolly: Employee; Tidepool. D.P. Zaharieva: Research Support; Hemsley Charitable Trust. Speaker’s Bureau; Dexcom, Inc. Research Support; Insulet Corporation, International Society for Pediatric and Adolescent Diabetes. B. Arbiter: Stock/Shareholder; Eli Lilly and Company, Dexcom, Inc. Employee; Tidepool. K. Watson: Employee; Tidepool. M. Friedman: None. L. Figg: None. A.L. Cortes-Navarro: None. I. Balistreri: None. R.S. Kingman: None. B. Suh: None. M.C. Riddell: Advisory Panel; Zucara Therapeutics, embecta. Consultant; Dexcom, Inc., Insulet Corporation, Eli Lilly and Company, Novo Nordisk. Speaker’s Bureau; Novo Nordisk, Dexcom, Inc., Sanofi, Eli Lilly and Company. Stock/Shareholder; Zucara Therapeutics. Research Support; Dexcom, Inc., Insulet Corporation, Eli Lilly and Company. Y. Qin: None.
The Leona M. & Harry B. Helmsley Charitable Trust Grant (2404-06905)
Source link
Leave a Reply